{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:41:49Z","timestamp":1763106109578,"version":"3.45.0"},"reference-count":118,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Environ Pathol Toxicol Oncol"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Neuro-oncology is the study of brain and spinal cord neoplasms. Molecular targets and signaling pathways are pivotal in advancing modern healthcare, particularly in personalized medicine. Signaling pathways, which regulate cellular processes such as growth, division, and survival, are frequently dysregulated in cancer. Targeting these pathways has enabled the development of personalized therapies that improve efficacy while minimizing side effects. This approach has led to significant improvements in patient outcomes, reduced treatment toxicity, and a shift toward precision medicine, driving innovation in drug discovery. The integration of molecular targets and signaling pathways into clinical practice highlights their importance for enhancing patient care.<\/p>","DOI":"10.1615\/jenvironpatholtoxicoloncol.2025059098","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:23:06Z","timestamp":1749032586000},"page":"81-96","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering Novel Molecular Targets in Neuro-Oncology: An Update"],"prefix":"10.1615","volume":"44","author":[{"given":"Kanishka Alagar","family":"Raja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunnathur Murugesan","family":"Sakthivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venugopal Vinod","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saradhadevi","family":"Muthukrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prema","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mythili","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan Radha","family":"Rasmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","unstructured":"Chamberlain MC. International neurology-neuro-oncology overview. In: Lisak RP, Truong D, Carroll WM, Bhidayasiri R, editors. International neurology. 2nd ed. Hoboken, NJ, USA: John Wiley & Sons, Ltd.; 2016."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Afonso M, Brito MA. Therapeutic options in neuro-oncology. Int J Mol Sci. 2022;23(10):5351.","DOI":"10.3390\/ijms23105351"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K\/Akt\/PTEN, mTOR, SHH\/PTCH and angiogenesis. Expert Rev Anticancer Ther. 2004;4(1):105-28.","DOI":"10.1586\/14737140.4.1.105"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: A new horizon. Lancet Oncol. 2013;14(9):e370-9.","DOI":"10.1016\/S1470-2045(13)70168-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231-51.","DOI":"10.1093\/neuonc\/noab106"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Smith HL, Wadhwani N, Horbinski C. Major features of the 2021 WHO classification of CNS tumors. Neurotherapeutics. 2022;19(6):1691-704.","DOI":"10.1007\/s13311-022-01249-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Polley MYC, Schwartz D, Karrison T, Dignam JJ. Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024;26(5):796-810.","DOI":"10.1093\/neuonc\/noae005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Luger AL, K\u00f6nig S, Samp PF, Urban H, Div\u00e9 I, Burger MC, Voss M, Franz K, Fokas E, Filipski K, Demes MC. Molecular matched targeted therapies for primary brain tumors-A single center retrospective analysis. J Neurooncol. 2022;159(2):243-59.","DOI":"10.1007\/s11060-022-04049-w"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, Niclou SP, Euskirchen P, Haberler C, Hegi ME, Brandner S. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 2023;25(5):813-26.","DOI":"10.1093\/neuonc\/noad008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Min H, Lee H. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670-94.","DOI":"10.1038\/s12276-022-00864-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188-96.","DOI":"10.1016\/j.ejphar.2018.07.034"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Muzyka L, Goff NK, Choudhary N, Koltz MT. Systematic review of molecular targeted therapies for adult-type diffuse glioma: An analysis of clinical and laboratory studies. Int J Mol Sci. 2023;24(13):10456.","DOI":"10.3390\/ijms241310456"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2019;57(1):20-6.","DOI":"10.1016\/j.resinv.2018.09.001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Zhang Q, Fu Q, Bai X, Liang T. Molecular profiling-based precision medicine in cancer: A review of current evidence and challenges. Front Oncol. 2020;10:532403.","DOI":"10.3389\/fonc.2020.532403"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-5.","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51(4):522-32.","DOI":"10.1016\/j.ejca.2014.12.019"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, B\u00e4hr O, Lombardi G. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023;25(1):123-34.","DOI":"10.1093\/neuonc\/noac099"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.","DOI":"10.1155\/2014\/357027"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Peters KB, Alford C, Heltemes A, Savelli A, Landi DB, Broadwater G, Desjardins A, Johnson MO, Low JT, Khasraw M, Ashley DM, Friedman HS, Patel MP. Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma. Neurooncol Pract. 2024;11(2):199-204.","DOI":"10.1093\/nop\/npad068"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Yang Z, Zhang Y, Li R, Yisikandaer A, Ren B, Sun J, Li J, Chen L, Zhao R, Zhang J, Xia X, Liao Z, Carbone DP. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: A multicenter, open-label, randomized, controlled phase III trial. Neuro Oncol. 2021;23(6):967-78.","DOI":"10.1093\/neuonc\/noaa281"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020;11(21):1942-52.","DOI":"10.18632\/oncotarget.27600"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Velasco G, Pineda E, Alameda F, Capellades J, Cruz M, Tovar Ambel E, Foro P, Taus A, Arumi M, Manuel J. Safety and efficacy of crizotinib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib GEINO 1402 trial. Cancers. 2022;14(10):2393.","DOI":"10.3390\/cancers14102393"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Brastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, Chukwueke UN, Mahar M, Oh K, White MD, Shih HA. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021;2(5):498-502.","DOI":"10.1038\/s43018-021-00198-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Brown NF, Ng SM, Brooks C, Coutts T, Holmes J, Roberts C, Elhussein L, Hoskin P, Maughan T, Blagden S, Mulholland P. A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: The Ipi-Glio trial protocol. BMC Cancer. 2020;20(1):198.","DOI":"10.1186\/s12885-020-6624-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"DeWire M, Lazow M, Campagne O, Leach J, Fuller C, Senthil Kumar S, Stanek J, De Blank P, Hummel TR, Pillay-Smiley N, Salloum R. Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neurooncol Adv. 2022;4(1):vdac055.","DOI":"10.1093\/noajnl\/vdac055"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Roth P, Pace A, Le Rhun E, Weller M, Ay C, Moyal EC, Coomans M, Giusti R, Jordan K, Nishikawa R, Winkler F. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO clinical practice guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):171-82.","DOI":"10.1016\/j.annonc.2020.11.003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Patel A. Benign vs. malignant tumors. JAMA Oncol. 2020;6(9):1488.","DOI":"10.1001\/jamaoncol.2020.2592"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432-46.","DOI":"10.1016\/S0140-6736(18)30990-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JE, Chang SM. Primary brain tumours in adults. Lancet. 2023;402(10412):1564-79.","DOI":"10.1016\/S0140-6736(23)01054-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR. The epidemiology of glioma in adults: A 'state of the science' review. Neuro Oncol. 2014;16(7):896-913.","DOI":"10.1093\/neuonc\/nou087"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Sievers P, Bielle F, G\u00f6bel K, Schrimpf D, Nichelli L, Mathon B, Appay R, Boldt HB, Dohmen H, Selignow C, Acker T. Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations. Acta Neuropathol. 2024;148:7.","DOI":"10.1007\/s00401-024-02766-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Alshoabi SA, Alareqi AA, Omer AM, Suliman AG, Daqqaq TS. Diffuse astrocytoma and the diagnostic dilemma of an unusual phenotype: A case report. Radiol Case Rep. 2021;16(2):319-26.","DOI":"10.1016\/j.radcr.2020.11.023"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Gilanie G, Bajwa UI, Waraich MM, Anwar MW. Riskfree WHO grading of astrocytoma using convolutional neural networks from MRI images. Multimed Tools Appl. 2021;80(3):4295-306.","DOI":"10.1007\/s11042-020-09970-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Liu S, Liu X, Zhuang W. Prognostic factors associated with survival in patients with diffuse astrocytoma. Front Surg. 2021;8:712350.","DOI":"10.3389\/fsurg.2021.712350"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Ruiz MF, Gennaro MV, Bastone LC, Godoy AR, Torruella M, Perez GR. Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. Mol Clin Oncol. 2021;15:150.","DOI":"10.3892\/mco.2021.2312"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, Maas SL, Kratz CP, Schweizer L, Hasselblatt M, Snuderl M. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2021;141:85-100.","DOI":"10.1007\/s00401-020-02243-6"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66(3):262-72.","DOI":"10.1016\/j.critrevonc.2007.11.007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Aboud O, Shah R, Vera E, Burton E, Theeler B, Wu J, Penas-Prado M. Challenges of imaging interpretation to predict oligodendroglioma grade: A report from the Neuro-Oncology Branch. CNS Oncol. 2022;11(1):CNS83.","DOI":"10.2217\/cns-2021-0005"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Jenkinson MD, Du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features. Brain. 2006;129(7):1884-91.","DOI":"10.1093\/brain\/awl108"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Van der Vaart T, Wijnenga MM, van Garderen K, Dubbink HJ, French PJ, Smits M, van den Bent MJ. Differences in the prognostic role of age, extent of resection, and tumor grade between astrocytoma IDHmt and oligodendroglioma: A single-center cohort study. Clin Cancer Res. 2024;30(17):3837-44.","DOI":"10.1158\/1078-0432.CCR-24-0901"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Cao L, Rong P, Zhu G, Xu A, Chen S. Clinical characteristics and overall survival prognostic nomogram for oligodendroglioma: A surveillance, epidemiology, and end results population-based analysis. World Neurosurg. 2021;151:e810-20.","DOI":"10.1016\/j.wneu.2021.04.122"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23(8):1231-51.","DOI":"10.1093\/neuonc\/noab106"},{"key":"44","unstructured":"Mut MEL\u0130KE, Guler-Tezel G, Lopes MBS, Bilginer BUR\u00c7AK, Ziyal I, Ozcan OE. Challenging diagnosis: Oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol. 2005;24(5):225."},{"key":"45","doi-asserted-by":"crossref","unstructured":"Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch Neurol. 1999;56(4):434-6.","DOI":"10.1001\/archneur.56.4.434"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: Clinical features, treatment, and prognosis. Surg Neurol. 2003;60(5):443-56.","DOI":"10.1016\/S0090-3019(03)00167-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66(3):262-72.","DOI":"10.1016\/j.critrevonc.2007.11.007"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, Simone TD, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer. 2006;119(1):84-90.","DOI":"10.1002\/ijc.21759"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394-401.","DOI":"10.1200\/JCO.2017.72.6737"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W. Farewell to oligoastrocytoma: In situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551-9.","DOI":"10.1007\/s00401-014-1326-7"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014;19(4):403-13","DOI":"10.1634\/theoncologist.2013-0345"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Lanman TA, Compton JN, Carroll KT, Hirshman BR, Ali MA, Lochte B, Carter B, Chen CC. Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis. Interdiscip Neurosurg. 2018;11:70-5.","DOI":"10.1016\/j.inat.2017.07.017"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Alther B, Mylius V, Weller M, Gantenbein AR. From first symptoms to diagnosis: Initial clinical presentation of primary brain tumors. Clin Transl Neurosci. 2020;4(2): 2514183X20968368.","DOI":"10.1177\/2514183X20968368"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol. 2003;62(2):111-26.","DOI":"10.1093\/jnen\/62.2.111"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman AB, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403-26.","DOI":"10.1200\/JCO.21.02036"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Taylor OG, Brzozowski JS, Skelding KA. Glioblastoma multiforme: An overview of emerging therapeutic targets. Front Oncol. 2019;9:486794.","DOI":"10.3389\/fonc.2019.00963"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Gibbs JB. Anticancer drug targets: Growth factors and growth factor signaling. J Clin Invest. 2000;105(1):9-13.","DOI":"10.1172\/JCI9084"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol. 2014;4:67531.","DOI":"10.3389\/fonc.2014.00064"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16.","DOI":"10.1016\/j.gene.2005.10.018"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: A systemic review and meta-analysis. Eur Radiol. 2019;29:745-58.","DOI":"10.1007\/s00330-018-5608-7"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Begagi\u0107 E, Pugonja R, Beculi\u0107 H, Celikovi\u0107 A, Tandir Lihi\u0107 L, Kadi\u0107 Vukas S, Cejvan L, Skomorac R, Selimovi\u0107 E, Jaganjac B, Jukovi\u0107-Bihorac F. Molecular targeted therapies in glioblastoma multiforme: A systematic overview of global trends and findings. Brain Sci. 2023;13(11):1602.","DOI":"10.3390\/brainsci13111602"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, Marini B, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C. Molecular profiling and targeted therapy in pediatric gliomas: Review and consensus recommendations. Neuro Oncol. 2019;21(8):968.","DOI":"10.1093\/neuonc\/noz022"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 2003;39(10):1348-54.","DOI":"10.1016\/S0959-8049(03)00235-1"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: Successes and limitations. Chin J Cancer. 2011;30(1):5.","DOI":"10.5732\/cjc.010.10542"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials. 2013;34(34):8690-707.","DOI":"10.1016\/j.biomaterials.2013.07.100"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006;12(24):7242-51.","DOI":"10.1158\/1078-0432.CCR-06-0646"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777-92.","DOI":"10.4161\/cbt.11.9.15050"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.","DOI":"10.1038\/nrc969"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29(6):1091-104.","DOI":"10.1038\/emboj.2010.7"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998;8(1):49-54.","DOI":"10.1016\/S0959-437X(98)80061-0"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457-67.","DOI":"10.1158\/0008-5472.CAN-11-2612"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969-74.","DOI":"10.1158\/0008-5472.CAN-19-3682"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Blum R, Kloog Y. Tailoring Ras-pathway-Inhibitor combinations for cancer therapy. Drug Resist Updates. 2005;8(6):369-80.","DOI":"10.1016\/j.drup.2005.11.002"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Sebti SM, Der CJ. Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer. 2003;3(12):945-51.","DOI":"10.1038\/nrc1234"},{"key":"75","unstructured":"Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res. 2003;63(18):5656-68."},{"key":"76","doi-asserted-by":"crossref","unstructured":"Dhillon S. Lonafarnib: First approval. Drugs. 2021;81: 283-9.","DOI":"10.1007\/s40265-020-01464-z"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014;16(5):707-18.","DOI":"10.1093\/neuonc\/nou004"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol. 2004;31:28-39.","DOI":"10.1053\/j.seminoncol.2003.12.012"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Cheng Y, Tian H. Current development status of MEK inhibitors. Molecules. 2017;22(10):1551.","DOI":"10.3390\/molecules22101551"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJ, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A. First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184-95.","DOI":"10.1158\/2159-8290.CD-17-1119"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Barbosa R, Acevedo LA, Marmorstein R. The MEK\/ERK network as a therapeutic target in human cancer. Mol Cancer Res. 2021;19(3):361-74.","DOI":"10.1158\/1541-7786.MCR-20-0687"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012;11(5):1143-54.","DOI":"10.1158\/1535-7163.MCT-11-1010"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, Ranieri E. The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: An updated review. Cancers. 2021;13(16):3949.","DOI":"10.3390\/cancers13163949"},{"key":"84","doi-asserted-by":"crossref","unstructured":"Alzahrani AS. PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019;59:125-32.","DOI":"10.1016\/j.semcancer.2019.07.009"},{"key":"85","doi-asserted-by":"crossref","unstructured":"Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 2004;9:667-76.","DOI":"10.1023\/B:APPT.0000045801.15585.dd"},{"key":"86","doi-asserted-by":"crossref","unstructured":"Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K\/AKT pathway in cancer: The framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587-629.","DOI":"10.1007\/s11033-020-05435-1"},{"key":"87","doi-asserted-by":"crossref","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M. NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68(19):8022-30.","DOI":"10.1158\/0008-5472.CAN-08-1385"},{"key":"88","doi-asserted-by":"crossref","unstructured":"Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, Picci P. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010;16(2):530-40.","DOI":"10.1158\/1078-0432.CCR-09-0816"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: A comparative review of PI3K\/AKT\/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021-31.","DOI":"10.1158\/1535-7163.MCT-13-0639"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Eckerdt FD, Bell JB, Gonzalez C, Oh MS, Perez RE, Mazewski C, Fischietti M, Goldman S, Nakano I, Platanias LC. Combined PI3Ka-mTOR targeting of glioma stem cells. Sci Rep. 2020;10(1):21873.","DOI":"10.1038\/s41598-020-78788-z"},{"key":"91","doi-asserted-by":"crossref","unstructured":"Zirlik K, Veelken H. Idelalisib. Recent Results Cancer Res. 2018;212:243-64.","DOI":"10.1007\/978-3-319-91439-8_12"},{"key":"92","doi-asserted-by":"crossref","unstructured":"De Gooijer MC, Zhang P, Buil LC, \u00c7itirikkaya CH, Thota N, Beijnen JH, Van Tellingen O. Buparlisib is a brain penetrable pan-PI3K inhibitor. Sci Rep. 2018;8(1):10784.","DOI":"10.1038\/s41598-018-29062-w"},{"key":"93","doi-asserted-by":"crossref","unstructured":"Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M, Tsatsakis AM. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use. Int J Oncol. 2015;48(3):869-85.","DOI":"10.3892\/ijo.2015.3306"},{"key":"94","doi-asserted-by":"crossref","unstructured":"Lopez-Miranda E, P\u00ef\u00bf\u00bd&copy;rez Garcia JM, Gion M, Ribelles N, Cortez P, Alonso Romero JL, Martinez-Garcia M, Gonzalez-Santiago S, Bermejo B, Morales Murillo S, Caranana V. Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial. 2024:1098.","DOI":"10.1200\/JCO.2024.42.16_suppl.1098"},{"key":"95","doi-asserted-by":"crossref","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960-76.","DOI":"10.1016\/j.cell.2017.02.004"},{"key":"96","doi-asserted-by":"crossref","unstructured":"Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589-94.","DOI":"10.1242\/jcs.051011"},{"key":"97","doi-asserted-by":"crossref","unstructured":"Wang X, Proud CG. MTORC1 signaling: What we still don't know. J Mol Cell Biol. 2011;3(4):206-20.","DOI":"10.1093\/jmcb\/mjq038"},{"key":"98","doi-asserted-by":"crossref","unstructured":"Ballesteros-Alvarez J, Andersen JK. MTORC2: The other mTOR in autophagy regulation. Aging Cell. 2021;20(8):e13431.","DOI":"10.1111\/acel.13431"},{"key":"99","doi-asserted-by":"crossref","unstructured":"Fu W, Hall MN. Regulation of mTORC2 signaling. Genes. 2020;11(9):1045.","DOI":"10.3390\/genes11091045"},{"key":"100","doi-asserted-by":"crossref","unstructured":"Anandappa G, Hollingdale A, Eisen T. Everolimus-A new approach in the treatment of renal cell carcinoma. Cancer Manag Res. 2010;2:61-70.","DOI":"10.2147\/CMAR.S6047"},{"key":"101","doi-asserted-by":"crossref","unstructured":"Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008;14(5):1286-90.","DOI":"10.1158\/1078-0432.CCR-07-4719"},{"key":"102","doi-asserted-by":"crossref","unstructured":"Sehgal S. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3):S7-14.","DOI":"10.1016\/S0041-1345(03)00211-2"},{"key":"103","doi-asserted-by":"crossref","unstructured":"Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059-71.","DOI":"10.1158\/1535-7163.MCT-10-0792"},{"key":"104","doi-asserted-by":"crossref","unstructured":"Carballo GB, Honorato JR, de Lopes GP, Spohr TC. A highlight on Sonic hedgehog pathway. Cell Commun Signal. 2018;16(1):11.","DOI":"10.1186\/s12964-018-0220-7"},{"key":"105","doi-asserted-by":"crossref","unstructured":"Lindstr\u00f6m E, Shimokawa T, Toftg\u00e5rd R, Zaphiropoulos PG. PTCH mutations: Distribution and analyses. Hum Mutat. 2006;27(3):215-9.","DOI":"10.1002\/humu.20296"},{"key":"106","doi-asserted-by":"crossref","unstructured":"Rubin LL, De Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5(12):1026-33","DOI":"10.1038\/nrd2086"},{"key":"107","doi-asserted-by":"crossref","unstructured":"Meiss F, Andrlov\u00e1 H, Zeiser R. Vismodegib. Recent Results Cancer Res. 2018;211:125-39.","DOI":"10.1007\/978-3-319-91442-8_9"},{"key":"108","doi-asserted-by":"crossref","unstructured":"Jain S, Song R, Xie J. Sonidegib: Mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. 2017;1645-53.","DOI":"10.2147\/OTT.S130910"},{"key":"109","doi-asserted-by":"crossref","unstructured":"Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388-99.","DOI":"10.1016\/j.ccr.2010.02.027"},{"key":"110","doi-asserted-by":"crossref","unstructured":"Huveneers S, Phng L. Endothelial cell mechanics and dynamics in angiogenesis. Curr Opin Cell Biol. 2024;91:102441.","DOI":"10.1016\/j.ceb.2024.102441"},{"key":"111","doi-asserted-by":"crossref","unstructured":"Ackermann M, Werlein C, Plucinski E, Leypold S, K\u00fchnel MP, Verleden SE, Khalil HA, L\u00e4nger F, Welte T, Mentzer SJ, Jonigk DD. The role of vasculature and angiogenesis in respiratory diseases. Angiogenesis. 2024;27(3): 293-310.","DOI":"10.1007\/s10456-024-09910-2"},{"key":"112","doi-asserted-by":"crossref","unstructured":"Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G. VEGF signaling: Role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer. 2024;1879(2):189079.","DOI":"10.1016\/j.bbcan.2024.189079"},{"key":"113","doi-asserted-by":"crossref","unstructured":"Laviv Y, Regev O, Kanner AA, Fichman S, Limon D, Siegal T, Yust-Katz S, Benouaich-Amiel A. Stem the blood flow: Beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients. J Neurooncol. 2025 Jan;171(1):201-11.","DOI":"10.1007\/s11060-024-04828-7"},{"key":"114","doi-asserted-by":"crossref","unstructured":"Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, Baumane K, Agarwal S, Oleksy P, Reichstein DA, Patel SS. Aflibercept biosimilar myl-1701p vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial. JAMA Ophthalmol. 2024;142(10):952-60.","DOI":"10.1001\/jamaophthalmol.2024.3458"},{"key":"115","doi-asserted-by":"crossref","unstructured":"Mongiardi MP, Pallini R, D'Alessandris QG, Levi A, Falchetti ML. Regorafenib and glioblastoma: A literature review of preclinical studies, molecular mechanisms and clinical effectiveness. Expert Rev Mol Med. 2024;26:e5.","DOI":"10.1017\/erm.2024.8"},{"key":"116","doi-asserted-by":"crossref","unstructured":"Purow B, Fine HA. Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest. 2004;22(4):577-87.","DOI":"10.1081\/CNV-200027141"},{"key":"117","doi-asserted-by":"crossref","unstructured":"Zhang AB, Mozaffari K, Aguirre B, Li V, Kubba R, Desai NC, Wei D, Yang I, Wadehra M. Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma. Cancers. 2023;15(3):830.","DOI":"10.3390\/cancers15030830"},{"key":"118","doi-asserted-by":"crossref","unstructured":"Nowacka A, Sniegocki M, Smuczy\u0144ski W, Bozilow D, Zi\u00f3lkowska E. Angiogenesis in glioblastoma-Treatment approaches. Cells. 2025;14(6):407.","DOI":"10.3390\/cells14060407"},{"key":"119","doi-asserted-by":"crossref","unstructured":"Pellerino A, Bruno F, Soffietti R, Rud\u00e0 R. Antiangiogenic therapy for malignant brain tumors: Does it still matter? Curr Oncol Rep. 2023;25(7):777-85.","DOI":"10.1007\/s11912-023-01417-1"}],"container-title":["Journal of Environmental Pathology, Toxicology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/2cdd69a51cbc647f\/JEP(T)-59098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:36:02Z","timestamp":1763105762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/0ff459a57a4c08d0,2398aadc50463bfa,2cdd69a51cbc647f.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/jenvironpatholtoxicoloncol.2025059098","relation":{},"ISSN":["0731-8898"],"issn-type":[{"type":"print","value":"0731-8898"}],"subject":[],"published":{"date-parts":[[2025]]}}}